Valuation: AstraZeneca PLC

Capitalization 282B 240B 219B 207B 386B 26,634B 389B 2,601B 1,014B 12,793B 1,058B 1,036B 44,168B P/E ratio 2026 *
22.9x
P/E ratio 2027 * 20.1x
Enterprise value 302B 256B 234B 221B 413B 28,482B 416B 2,781B 1,084B 13,681B 1,131B 1,108B 47,232B EV / Sales 2026 *
4.76x
EV / Sales 2027 * 4.36x
Free-Float
96.62%
Yield 2026 *
1.83%
Yield 2027 * 1.94%
1 day+2.09%
1 week+1.80%
Current month-2.71%
1 month-9.46%
3 months-8.42%
6 months+0.77%
Current year-1.60%
1 week 13,188
Extreme 13188
13,708
1 month 12,356
Extreme 12356
15,130
Current year 12,356
Extreme 12356
15,732
1 year 9,651
Extreme 9651
15,732
3 years 9,461
Extreme 9461
15,732
5 years 7,642
Extreme 7642
15,732
10 years 3,680
Extreme 3680
15,732
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5d. change 1-year change 3-years change Capi.($)
+2.09%+1.80%+32.11%+13.80% 282B
+3.74%+0.88%+29.24%+124.19% 846B
+0.57%-1.07%+43.90%+37.78% 533B
+1.20%-2.09%+7.22%+39.03% 356B
+1.65%-0.97%+22.40%+12.53% 324B
+0.85%+0.37%+24.63%+23.42% 278B
+1.87%-0.44%+40.02%-4.20% 275B
+4.19%+5.99%-32.06%-48.10% 203B
+0.34%+2.24%+20.51%+42.54% 179B
+2.32%+1.05%+29.15%+70.37% 163B
Average +1.88%-0.63%+21.71%+31.14% 343.84B
Weighted average by Cap. +2.02%-1.12%+25.24%+47.03%

Financials

2026 *2027 *
Net sales 63.41B 53.88B 49.31B 46.54B 86.81B 5,989B 87.57B 585B 228B 2,877B 238B 233B 9,932B 67.31B 57.19B 52.34B 49.4B 92.14B 6,357B 92.95B 621B 242B 3,053B 253B 247B 10,542B
Net income 12.47B 10.59B 9.69B 9.15B 17.07B 1,177B 17.22B 115B 44.82B 566B 46.77B 45.79B 1,952B 14.12B 11.99B 10.98B 10.36B 19.32B 1,333B 19.49B 130B 50.75B 640B 52.96B 51.84B 2,211B
Net Debt 19.56B 16.62B 15.21B 14.36B 26.78B 1,848B 27.02B 180B 70.33B 887B 73.39B 71.85B 3,064B 11.5B 9.77B 8.94B 8.44B 15.74B 1,086B 15.87B 106B 41.33B 521B 43.13B 42.22B 1,800B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
11/05/26 13,572.00 p +1.71% 365,571
08/05/26 13,344.00 p +0.23% 2,521,880
07/05/26 13,314.00 p -1.86% 2,842,538
06/05/26 13,566.00 p +1.77% 1,618,146
05/05/26 13,330.00 p -1.35% 3,364,744
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
181.83USD
Average target price
221.63USD
Spread / Average Target
+21.89%

Quarterly revenue - Rate of surprise